Also, a combined therapy involving atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular endothelial growth factor (VEGF)) presents acceptable effects in HCC treatment [14]. The gene discussed is CD274; the disease is hepatocellular carcinoma.